ArticleCommunications biology2024
Author Correction: NIPBL-mediated RAD21 facilitates tumorigenicity by the PI3K pathway in non-small-cell lung cancer.
Xiaoling Xu, Ding Wang, Weizhen Xu, Huihui Li, Ning Chen, Na Li, Qifeng Yao, Wei Chen, Jianxiang Zhong, Weimin Mao
Open access · goldAbstract readPublished Erratum
In one paragraphArticle in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
10 authors at 5 institutions in 2 countries.
Xiaoling XuDepartment of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 507 Zhengmin Road, Shanghai, China.
Ding WangKey laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Zhejiang Cancer Research Institute, 38 Guangji Road, Hangzhou, China.
Weizhen XuKey laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Zhejiang Cancer Research Institute, 38 Guangji Road, Hangzhou, China.
Huihui LiKey laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Zhejiang Cancer Research Institute, 38 Guangji Road, Hangzhou, China.
Ning ChenThe Second Clinical Medical College of Zhejiang Chinese Medical University, 548 Binwen Road, Hangzhou, China.
Na LiThe Second Clinical Medical College of Wenzhou Medical University, 268 West Xueyue Road, Wenzhou, China.
Qifeng YaoThe Second Clinical Medical College of Wenzhou Medical University, 268 West Xueyue Road, Wenzhou, China.
Wei ChenKey laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Zhejiang Cancer Research Institute, 38 Guangji Road, Hangzhou, China. chenwei@zjcc.org.cn.ORCID http://orcid.org/0000-0003-0801-5613 Weimin MaoKey laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Zhejiang Cancer Research Institute, 38 Guangji Road, Hangzhou, China. maowm1318@163.com.ORCID http://orcid.org/0000-0001-8894-2497 Wenzhou Medical University · CNZhejiang Cancer Hospital · CNSoutheast University · BDTongji University · CNZhejiang Chinese Medical University · CN
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID38561443
PMCPMC10985063
OpenAlexW4393373038
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390